Pioneers Tackling Interchangeability in Biosimilars
With a global market of USD 3.3 billion during 2016 and a forecast surpassing USD […]
17
11, 2017
26
06, 2017
The Decision on Timing in the BPCI Act
This week, the path to market for biosimilar developers cleared up just a bit. The Supreme […]
9
01, 2017
Clinical Endpoint ANDA Program Optimization Introduction
This introduction marks the launch of a series of White Papers dealing with the optimization of Clinical Endpoint ANDA Programs for the generics and specialty pharmaceutical industry.
4
11, 2016
3 Trends in Biosimilars: A 6-Year Outlook
Over the next five years, the purchase and production of biosimilar […]
28
09, 2016
The Promise of Biosimilar Drugs
In 2006, the European Medicines Agency granted its first approval of a biosimilar drug, the human growth hormone, […]
31
08, 2016
Biorasi Joins GPhA Biosimilars Council to Promote Biosimilar Drug Development
There is great strength in numbers, and joining forces with some of the world’s most influential […]
16
03, 2015
Making Room for Biosimilars
Co-authored by Stephanie Finnegan, President Divisional Operations and Dominique James, Editorial Analyst
On March 6th, 2015 the […]
10
03, 2015
Life in the Era of Follow On Biologics
Biorasi has run as many biologics trials as they have small-molecule drug trials; a standout feature of our study experience that makes us unique.
